VENKATA KRISHNA JAYANTH PARSA
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology FORT MYERS, FL NPI 1518156959
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology FL Intera Oncology, Inc All categories
General Payments — all program years on this page
$1,764.94
- Category: General Payments
- Program years: PY2019–2024
- Record count: 68
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $717.38 across 29 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $717.38 | 29 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Intera Oncology, Inc | $68.70 | 1 |
| Fennec Pharmaceuticals, Inc. | $49.28 | 3 |
| Incyte Corporation | $48.87 | 2 |
| Rigel Pharmaceuticals, Inc. | $47.28 | 1 |
| ADC Therapeutics America, Inc. | $36.21 | 1 |
| Astellas Pharma US Inc | $34.65 | 2 |
| ABBVIE INC. | $34.26 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34.09 | 1 |
| GlaxoSmithKline, LLC. | $32.47 | 1 |
| Stemline Therapeutics Inc. | $29.95 | 1 |
| Blueprint Medicines Corporation | $29.68 | 1 |
| EISAI INC. | $27.59 | 2 |
| Daiichi Sankyo Inc. | $27.06 | 1 |
| Regeneron Healthcare Solutions, Inc. | $26.21 | 1 |
| E.R. Squibb & Sons, L.L.C. | $24.60 | 1 |
| Gilead Sciences, Inc. | $22.65 | 1 |
| SpringWorks Therapeutics, Inc. | $22.05 | 1 |
| GENZYME CORPORATION | $21.27 | 1 |
| Alexion Pharmaceuticals, Inc. | $20.24 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.12 | 1 |
| Karyopharm Therapeutics Inc. | $16.54 | 1 |
| SOBI, INC | $15.61 | 1 |
| TAIHO ONCOLOGY, INC. | $15.14 | 1 |
| Acrotech Biopharma Inc. | $14.86 | 1 |
By program year
Records — PY2024 (29)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.